Medical Information
United States

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Información selecta para pacientes y cuidadores que se encuentra disponible en Español.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

DETROL® LA Highlights (tolterodine tartrate)


These highlights do not include all the information needed to use Detrol® LA safely and effectively. See full prescribing information for Detrol LA.

Detrol® LA (tolterodine tartrate extended release capsules)
For oral administration
Initial U.S. Approval: December 2000


DETROL LA is an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. (1)


  • 4 mg capsules taken orally once daily with water and swallowed whole. (2.1)
  • 2 mg capsules taken orally once daily with water and swallowed whole in the presence of:
    • mild to moderate hepatic impairment (Child-Pugh class A or B) (2.2)
    • severe renal impairment [Creatinine Clearance (CCr) 10–30 mL/min] (2.2)
    • drugs that are potent CYP3A4 inhibitors. (2.2)
  • DETROL LA is not recommended for use in patients with CCr <10 mL/min. (2.2)
  • DETROL LA is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C). (2.2)


Capsules: 2 mg and 4 mg (3)


DETROL LA is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. DETROL LA is also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like DETROL LA, are metabolized to 5-hydroxymethyl tolterodine. (4)


  • Anaphylaxis and angioedema requiring hospitalization and emergency medical treatment have occurred with the first or subsequent doses of DETROL LA. (5.1)
  • Urinary Retention: use caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention. (5.2)
  • Gastrointestinal Disorders: use caution in patients with gastrointestinal obstructive disorders or decreased gastrointestinal motility because of the risk of gastric retention. (5.3)
  • Controlled Narrow-Angle Glaucoma: use caution in patients being treated for narrow-angle glaucoma. (5.4)
  • Central Nervous System Effects: Somnolence has been reported with Detrol LA. Advise patients not to drive or operate heavy machinery until they know how Detrol LA affects them (5.5).
  • Myasthenia Gravis: use caution in patients with myasthenia gravis. (5.8)
  • QT Prolongation: consider observations from the thorough QT study in clinical decisions to prescribe DETROL LA to patients with a known history of QT prolongation or to patients who are taking Class IA (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications. (5.9)


The most common adverse reactions (incidence ≥4% and >placebo) were dry mouth, headache, constipation, and abdominal pain. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or


  • Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to DETROL LA. Reduce DETROL LA dose to 2 mg once daily. (7.2)
  • Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7.6)


  • Renal Impairment: DETROL LA is not recommended for use in patients with CCr <10 mL/min. Dose adjustment in severe renal impairment (CCr: 10–30 mL/min). (8.6)
  • Hepatic Impairment: Not recommended for use in severe hepatic impairment (Child Pugh Class C). Dose adjustment in mild to moderate hepatic impairment (Child Pugh Class A, B). (8.7)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 7/2018

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event